Odor Identification Ability Predicts PET Amyloid Status and Memory Decline in Older Adults.

BACKGROUND Odor identification deficits occur in Alzheimer's disease (AD), as measured by the 40-item University of Pennsylvania Smell Identification Test (UPSIT). OBJECTIVE To determine if UPSIT scores predict amyloid-β (Aβ) status, determined by 11C-Pittsburgh Compound B PET. We also compared UPSIT scores to Aβ status in predicting future memory decline. METHODS Subjects were recruited into a longitudinal clinical prediction study. We analyzed data from those who had UPSIT, cognitive testing, PIB PET, and at least 12 months' clinical follow-up. Forty-six amnestic mild cognitive impairment patients and 25 cognitively normal controls were included. Amyloid-positivity was defined as composite PIB standardized uptake value ratio >1.5. Logistic regression and Receiver Operating Characteristic Curve analyses tested the predictive utility of impaired olfaction (defined as UPSIT score <35) and amyloid-positivity for memory decline. RESULTS High UPSIT scores predicted absence of amyloidosis on PET, with negative predictive value of 100%. Positive predictive value of low UPSIT scores on positive Aβ status was only 41%. Both low UPSIT score (OR = 4.301, 95% CI = 1.248, 14.821, p = 0.021) and positive PET scan (OR = 20.898, 95% CI = 2.222, 196.581, p = 0.008) predicted memory decline. CONCLUSION Individuals with high UPSIT scores are less likely to have cerebral amyloidosis or experience memory decline. Therefore, UPSIT has potential as a screening tool to determine utility of Aβ PET in clinical practice or enrollment in clinical trials. Low UPSIT score is a non-specific marker of neurodegeneration that could indicate further workup in patients with memory complaints.

[1]  W. Goette,et al.  The relationship between smell identification and neuropsychological domains: Results from a sample of community-dwelling adults suspected of dementia , 2018, Journal of clinical and experimental neuropsychology.

[2]  C. Jack,et al.  Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals , 2017, Annals of neurology.

[3]  Keith A. Johnson,et al.  Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly , 2016, Annals of neurology.

[4]  C. Rowe,et al.  Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study , 2016, The Lancet Neurology.

[5]  Stefanie Schreiber,et al.  Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. , 2015, JAMA neurology.

[6]  A. Brickman,et al.  Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites. , 2015, Current Alzheimer research.

[7]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[8]  Keith A. Johnson,et al.  Odor identification and Alzheimer disease biomarkers in clinically normal elderly , 2015, Neurology.

[9]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[10]  A. Carvalho,et al.  Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. , 2015, CNS & neurological disorders drug targets.

[11]  Yaakov Stern,et al.  Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community , 2015, Neurology.

[12]  J. S. Payá,et al.  Alzheimer Disease Cerebrospinal Fluid Biomarkers Predict Cognitive Decline In Healthy Elderly Over 2 Years , 2014, Alzheimer disease and associated disorders.

[13]  A. Masurkar,et al.  Olfactory Dysfunction in the Elderly: Basic Circuitry and Alterations with Normal Aging and Alzheimer’s Disease , 2014, Current Geriatrics Reports.

[14]  George Jewell,et al.  Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study , 2014, Molecular Psychiatry.

[15]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[16]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[17]  Andrea Falini,et al.  Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. , 2011, American journal of respiratory and critical care medicine.

[18]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[20]  M. Albert,et al.  Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. , 2011, Archives of neurology.

[21]  Greg Savage,et al.  Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study. , 2011, Journal of Alzheimer's disease : JAD.

[22]  Charles DeCarli,et al.  Olfactory identification deficits and MCI in a multi-ethnic elderly community sample , 2010, Neurobiology of Aging.

[23]  M. Sarazin,et al.  Faculty Opinions recommendation of Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. , 2009 .

[24]  Jeffrey A. James,et al.  Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.

[25]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[26]  D A Bennett,et al.  The relationship between cerebral Alzheimer’s disease pathology and odour identification in old age , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[28]  B. Hyman,et al.  Pathologic Changes in the Olfactory System in Aging and Alzheimer's Disease a , 1991, Annals of the New York Academy of Sciences.

[29]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[30]  Richard L. Doty,et al.  Presence of both odor identification and detection deficits in alzheimer's disease , 1987, Brain Research Bulletin.

[31]  R. Doty,et al.  Smell identification ability: changes with age. , 1984, Science.

[32]  R. Doty,et al.  Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function , 1984, Physiology & Behavior.

[33]  B. Rourke,et al.  Central processing deficiencies in children: toward a developmental neuropsychological model. , 1982, Journal of clinical neuropsychology.

[34]  Ronald C Petersen,et al.  Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia. , 2016, JAMA neurology.

[35]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[36]  H. Braak,et al.  Olfactory bulb changes in Alzheimer's disease , 2004, Acta Neuropathologica.